A better buy-in window may exist right now for Protalix BioTherapeutics Inc. (PLX)

With 1.44 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.2 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.2800 whereas the lowest price it dropped to was $2.2201. The 52-week range on PLX shows that it touched its highest point at $3.55 and its lowest point at $1.00 during that stretch. It currently has a 1-year price target of $16.00. Beta for the stock currently stands at 1.46.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PLX was down-trending over the past week, with a drop of -3.39%, but this was down by -8.43% over a month. Three-month performance surged to 34.12% while six-month performance rose 115.09%. The stock gained 107.27% in the past year, while it has gained 66.42% so far this year. A look at the trailing 12-month EPS for PLX yields -0.31 with Next year EPS estimates of 0.63. For the next quarter, that number is -0.15. This implies an EPS growth rate of 50.70% for this year and 293.75% for next year. EPS is expected to grow by 25.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 45.40%.

Float and Shares Shorts:

At present, 57.48 million PLX shares are outstanding with a float of 41.75 million shares on hand for trading. On Apr 27, 2023, short shares totaled 7.43 million, which was 11.99% higher than short shares on Mar 30, 2023. In addition to Mr. Dror Bashan as the firm’s Pres, CEO & Director, Mr. Eyal Rubin M.B.A. serves as its Sr. VP, CFO, Treasurer & Corp. Sec.

Institutional Ownership:

Through their ownership of 9.05% of PLX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.54% of PLX, in contrast to 3.98% held by mutual funds. Shares owned by individuals account for 2.62%. As the largest shareholder in PLX with 1.85% of the stake, Renaissance Technologies LLC holds 1,209,750 shares worth 1,209,750. A second-largest stockholder of PLX, Medical Strategy GmbH, holds 1,135,407 shares, controlling over 1.74% of the firm’s shares. Meitav Mutual Funds Ltd. is the third largest shareholder in PLX, holding 244,332 shares or 0.37% stake. With a 1.49% stake in PLX, the FCP Medical – BioHealth is the largest stakeholder. A total of 974,747 shares are owned by the mutual fund manager. The APO Medical Opportunities, which owns about 0.32% of PLX stock, is the second-largest Mutual Fund holder. It holds 211,650 shares valued at 0.59 million. RIM Global – Bioscience holds 0.25% of the stake in PLX, owning 160,660 shares worth 0.45 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, PLX reported revenue of $8.75M and operating income of -$5.52M. The EBITDA in the recently reported quarter was -$4.44M and diluted EPS was -$0.11.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PLX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PLX analysts setting a high price target of $16.00 and a low target of $16.00, the average target price over the next 12 months is $16.00. Based on these targets, PLX could surge 601.75% to reach the target high and rise by 601.75% to reach the target low. Reaching the average price target will result in a growth of 601.75% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded PLX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 110,000 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *